DOI: https://doi.org/10.26641/2307-0404.2018.2(part1).129519

Galectin-3, advanced glycated end-products serum levels, endothelial function and cardiac hemo¬dynamics in post infarction heart failure patients with reduced and preserved ejection fraction.

O. Kuryata, A. Zabida, O. Sirenko

Abstract


Epidemiological studies have reported that the rate of signs and symptoms of heart failure after myocardial infarction is approximately 25%. In addition, approximately 40% of myocardial infarctions are accompanied by left ventricular systolic dysfunction. Aim.. Aim of the study is to evaluate serum levels of galactin-3, AGEs and endothelial function, cardiac hemodynamics in post infarction chronic heart failure patients with different ejection fraction. Materials and methods. All patients are divided into two main groups according to ejection fraction:1st group-20 patients with chronic heart failure with preserved ejection fraction, 2nd group-15 patients with chronic heart failure and reduced ejection fraction. Standard laboratory blood tests for erythrocyte sedimentation rate, haematological parameters, lipid profile, glucose, renal function, echocardiographic examination, endothelial function determine were performed for all patients. AGEs and galectin-3 serum levels were determined. Results. Patients with chronic heart failure and reduced ejection fraction and myocardial infarction in anamnesis had significantly increased left ventricle diastolic volume, left ventricle systolic volume,left ventricle diastolic dimension and left ventricle systolic dimension (p<0.05).AGEs serum level mildly increased in both groups.Galectin-3 level was significantly higher in pts with chronic heart failure and reduced ejection fraction(p < 0.05)and was correlated with age(R=0.74, p<0.05), left ventricle end diastolic volume (R=0.57, p<0.05), left ventricle end diastolic dimension (R=0.48, p<0.05), triglycerides level (R=0.45, p < 0.05). Most of the patients with chronic heart failure with myocardial infarction in anamnesis had endothelial dysfunction, the FMD% level was significantly higher in patients with preserved ejection fraction(p<0.05). Conclusions. Patients with chronic heart failure and reduced ejection fraction are characterized by significantly higher levels of galectin-3, endothelial dysfunction frequency, cardiac hemodynamics abnormalities.


Keywords


postinfarction chronic heart failure; galectin-3; AGEs; endothelial dysfunction; cardiac hemodynamics

Full Text:

PDF

References


Hartog JW, Voors AA, Bakker SJ, et al. Advan­ced glycation endproducts (AGEs) and heart failure: pathophysiology and clinicalimplications. Eur J Heart Fail. 2007;9:1146-55. doi: 10.1016/j.ejheart.2007.09.009

Albert NM, Lewis C. Recognizing and managing asymptomatic left ventricular dysfunction: after myo­cardial infarction. Crit CareNurse. 2008;28:20-37.

Thijssen DHJ, Black MA, Pyke K, Padilla J, At­kinson GA, Harris RA, Parker B, Widlansky ME, Tscha­kovsky ME, Green DJ. Assessment of flow mediated dilation (fmd) in humans: a methodological and phy­siological guideline. Am J Physiol Heart Circ Physiol. 2011;300:H2–H12. doi: 10.1152/ajpheart.00471.2010

Lindsey JB, de Lemos JA, Cipollone F, et al. Association between circulating soluble receptor for ad­vanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care. 2009;32:1218-20. doi: 10.2337/dc09-0053

Bauersachs J, Widder JD. Endothelial dysfunction in heart failure. Pharmacol Rep 2008;60:119-26.

Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. doi: 10.1093/eurheartj/ehs104

Jiang JX, Chen X, Hsu DK, et al. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Phy­siol. 2012;302:G439-46. doi: 10.1152/ajpgi.00257.2011

Møller JE, Whalley GA, Dini FL, et al. Inde­pendentprognostic importance of a restrictive left ventri-cularfilling pattern after myocardial infarction: an in­dividual patientmeta-analysis: Meta-Analysis Research Group in Echocardiographyacute myocardial infarction. Circulation. 2008;117:2591-8. doi: 10.1161/CIRCULA­TIONAHA.107.738625. Epub 2008 May 12.

Kuryata OV, Abdunaser A Zabida. Effect of L-Ar­ginine on the Serum Level of Advanced Glycation End Products in Patients with Post Infarction Chronic Heart Failure.Journal of Nutritional Therapeutics. 2017;6(2):43-50.

Kuryata O, Sirenko O. Endothelial function, insu­lin resistance, serum adiponectin level in rheumatoid arthritis females with renal dysfunction and its dynamics with L-arginine aspartate supplementation. Prensa Med Argent. 2017;103:6.

Kuryata O, Sirenko O. The inter relation of in­sulin resistance, serum adiponectin level in rheumatoid arthritis hypertensive females with subclinical athero­sclerosis and its dynamics with the endothelial dysfunc­tion correction. Orthopaedic Surgery and Traumatology. 2017;1(5):162-73.

Liu FT, Rabinovich GA. Galectins: regulators of acute and chronic inflammation. Ann NY Acad Sci. 2010;1183:158-82. doi: 10.1111/j.1749-6632.2009.05131.x

Falcone C, Emanuele E, D'Angelo A, et al. Plas­ma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032-7. doi: 10.1136/thx.2008.095588

Blair JE, Manuchehry A, Chana A, et al. Progno­stic markers in heart failure – congestion, neurohormones, and the cardiorenal syndrome. Acute Card Care. 2007;9:207-13. https://doi.org/10.1080/17482940701606913

Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, anovel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323-8.

Ramasamy R, Yan SF, Schmidt AM. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids. 2010;19. doi: 10.1007/s10741-010-9225-z

Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigo­rian-Shamagian L, et al. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: new roles for soluble RAGE. Eur J Heart Fail. 2010;12:1092-100. doi: 10.1093/eurjhf/hfq117


GOST Style Citations


  1. Advanced glycation endproducts (AGEs) and heart failure: pathophysiology and clinical implications / J.W. Hartog, A.A. Voors, S.J. Bakker, [et al.] // Eur. J. Heart. Fail. – 2007. – Vol. 9. – P. 1146-55. doi: 10.1016/j.ejheart.2007.09.009
  2. Albert NM. Recognizing and managing asym­ptomatic left ventricular dysfunction: after myocardial infarction / N.M. Albert, C. Lewis // Crit. Care. Nurse. – 2008. – Vol. 28. – P. 20-37.
  3. Assessment of flow mediated dilation (fmd) in humans: a methodological and physiological guideline / D.H.J. Thijssen, M.A. Black, K. Pyke, J. Padilla [et al.] // Am. J. Physiol Heart Circ Physiol. – 2011. – Vol. 300. – H2–H12. doi: 10.1152/ajpheart.00471.2010
  4. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study / J.B. Lindsey, J.A. de Lemos, F. Cipollone [et al.] // Diabetes Care. – 2009. – Vol. 32. – P. 1218-1220. doi: 10.2337/dc09-0053
  5. Bauersachs J. Endothelial dysfunction in heart failure / J. Bauersachs, J.D.Widder // Pharmacol Rep. – 2008. – Vol. 60. – P. 119-126.
  6. ESC Guidelines for the diagnosis and treatment The Task Force for the Diagnosis and Treat­ment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed in collaboration with the Heart Failure Association (HFA) of the ESC / P. Ponikowski [et al.] // Eur. Heart. J. – 2016. – Vol. 37, N 27. – P. 2129-200. doi: 10.1093/eurheartj/ehs104
  7. Galectin-3 modulates phagocytosis-induced stel­late cell activation and liver fibrosis in vivo / J.X. Jiang, X. Chen, D.K. Hsu [et al.] // Am. J. Physiol Gastrointest Liver Physiol. – 2012. – Vol. 302. – P. 439-446. doi: 10.1152/ajpgi.00257.2011
  8. Independentprognostic importance of a restrictive left ventricularfilling pattern after myocardial infarction: an individual patientmeta-analysis: Meta-Analysis Re­search Group in Echocardiographyacute myocardial infarction / J.E. Møller, G.A. Whalley, F.L. Dini [et al.] // Circulation. – 2008. – Vol. 117. – P. 2591-2598. doi: 10.1016/j.amjmed.2005.08.010
  9. Kuryata O.V. Effect of L-Arginine on the Serum Level of Advanced Glycation End Products in Patients with Post Infarction Chronic Heart Failure / O.V. Ku­ryata, Abdunaser A. Zabida // J. Nutritional Therapeutics. – 2017. – Vol. 6, N 2. – P. 43-50.
  10. Kuryata O. Endothelial Function, Insulin Resis­tance, Serum Adiponectin Level in Rheumatoid Arthritis Females with RenalDysfunction and Its Dynamics with L-Arginine Aspartate Supplementation / O. Kuryata, O. Si­renko // Prensa Med Argent. – 2017. – Vol. 103. – P. 6.
  11. Kuryata O. The inter relation of insulin resistance, serum adiponectin level in rheumatoid arthritis hyper­tensive females with subclinical atherosclerosis and its dynamics with the endothelial dysfunction correction // O. Ku­ryata, O. Sirenko / Orthop. Surgery Traumatol. – 2017. – Vol. 1, N 5. – P. 162-173.
  12. Liu F.T. Galectins: regulators of acute and chro­nic inflammation / F.T. Liu, G.A. Rabinovich // Acad Sci. –  2010. – Vol. 1183. – P. 158-82. doi: 10.1111/j.1749-6632.2009.05131.x
  13. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men / C. Falcone, E. Emanuele, A. D'Angelo [et al.] // Arterioscler Thromb Vasc Biol. –  2005. – Vol. 25. – P. 1032-7. doi: 10.1136/thx.2008.095588
  14. Prognostic markers in heart failure - congestion, neurohormones, and the cardiorenal syndrome / J.E. Blair, A. Manuchehry, A. Chana [et al.] // Acute Card Care. –  2007. – Vol. 9. – P. 207-213. https://doi.org/10.1080/­17482940701606913
  15. Prognostic value of galectin-3, anovel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study / D.J. Lok, P. Van Der Meer, P.W. de la Porte [et al.] // Clin. Res. Cardiol. – 2010. – Vol. 99. – P. 323-328.  doi: 10.1007/s00392-010-0125-y
  16. Ramasamy R. Advanced glycation endproducts: from precursors to RAGE: round and round we go / R. Ramasamy, S.F. Yan, A.M. Schmidt // Amino Acids. – 2010. – 19. doi: 10.1007/s10741-010-9225-z
  17. Soluble receptor of advanced glycation end pro­ducts levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, in­dependent of advanced glycation end products levels: new roles for soluble RAGE / S. Raposeiras-Roubín, B.K. Ro­diño-Janeiro, L. Grigorian-Shamagian [et al.] // Eur. J. Heart. Fail. – 2010. – Vol. 12. – P. 1092-100. doi: 10.1093/eurjhf/hfq117